Upadacitinib for autoimmune cholangitis and atopic dermatitis with itching
Treatments studied
Part of Digestive system, Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a drug called upadacitinib for people who have both a liver condition (primary biliary cholangitis or primary sclerosing cholangitis) and atopic dermatitis (eczema) with moderate to severe itching. The goal is to see if the drug can help control both the liver and skin problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have atopic dermatitis (eczema) that has been present for more than 6 months, with moderate to severe itching (a score of 4 or higher on a 0-10 itch scale).
- You have either primary biliary cholangitis or primary sclerosing cholangitis, as diagnosed by your doctor, and you have elevated liver enzymes.
- You have already tried standard treatments for your liver condition, including ursodeoxycholic acid for at least 12 months and at least two other treatments for at least 3 months.
- You do not have severe liver damage, active hepatitis B or C, or other serious liver diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding prednisone (a steroid) to ursodeoxycholic acid (a bile acid medicine) for people with primary biliary cholangitis who have a specific type of liver inflammation. The goal is to see if the combination works better at controlling the disease than standard care.
This study tests if the medication upadacitinib can help people whose eyelid rash has not improved with prescription creams. It's for adults who have had eyelid dermatitis for at least two months and have tried at least one prescribed cream that didn't work.
This trial tests a new medication, TH104, to see if it can reduce itching caused by primary biliary cholangitis (PBC). Itching is a common symptom of PBC, and this study aims to find a more effective treatment.
This trial provides early access to a medication called upadacitinib for people who have no other suitable treatment options and cannot join a clinical trial. Upadacitinib may help manage certain conditions when standard treatments have not worked.
This trial tests whether upadacitinib, an oral medication, is safe and effective for people with relapsing polychondritis that hasn't improved enough with standard treatments. It aims to reduce inflammation and control symptoms.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
Hear when a new Primary Biliary Cholangitis (PBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.